Build, Scale, and Transform Healthcare Companies
Hudson Healthcare Partners advises and executes across U.S. market entry, company building, and strategic transactions for pharmaceutical and biotech companies globally.
We don’t just advise—we build, structure, and execute.
Integrated Strategy, Execution, and Capital
We work at the intersection of strategy, operations, and transactions to help healthcare companies enter new markets, build platforms, and unlock value.
Our work centers on three areas:
U.S. Market Entry
Company Building & Transformation
Company Building & Transformation
We advise ex-U.S. pharmaceutical and biotech companies on how to successfully enter and scale in the United States.
- Market entry strategy and structuring
- Partner selection, licensing, and distribution models
- Phased build of U.S. commercial and operating capabilities
- Transition from partnership to direct presence
From access to full platform build—we guide the entire journey.
Company Building & Transformation
Company Building & Transformation
Company Building & Transformation
We build/rebuild healthcare companies.
- Newco formation around assets and platforms
- Development of operating strategy and infrastructure
- Team build and organizational design
- Turnaround and repositioning of underperforming businesses
We translate strategy into operating companies—not just plans.
Strategic & Transaction Advisory
Company Building & Transformation
Strategic & Transaction Advisory
We execute the transactions that define growth.
- M&A (buy-side and sell-side)
- Product acquisitions and divestitures
- In-licensing and out-licensing
- Strategic partnerships and capital formation
We combine deal expertise with operating insight—ensuring transactions work in practice, not just on paper.
Execution-Oriented Approach
Our model is simple:
Strategy alone is not enough. Execution drives value.
We differentiate by:
- Working from strategy through implementation
- Combining advisory with operating and transaction execution
- Aligning capital, capabilities, and long-term positioning
We ask three core questions in every engagement:
- What capabilities must you own vs. access?
- How do you align strategy, capital, and execution?
- How does this position your company 3–5 years out—not just at launch?
We partner with:
- Ex-U.S. pharmaceutical and biotech companies entering the U.S.
- Emerging companies building new platforms
- Established businesses undergoing transformation
- Investors and sponsors seeking operating and strategic expertise
Whether you are evaluating U.S. market entry, building a company, or executing a strategic transaction—we bring experience across the full lifecycle.